EBV-EA (residues 306-390)
Epstein-Barr Virus Early Antigen recombinant, *E. coli*

<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>PR-1224</td>
<td>100 µg</td>
</tr>
</tbody>
</table>

For general laboratory use.

**Shipping:** shipped on gel packs

**Storage Conditions:** store at -20 °C

**Additional Storage Conditions:** avoid freeze/thaw cycles

**Shelf Life:** 12 months

**Molecular Weight:** 35.5 kDa

**Purity:** > 95 % (SDS-PAGE)

**Form:** liquid (Supplied in 50 mM Tris-HCl pH 8.0, 10 mM glutathione, 60 mM NaCl and 0.5% sarcosyl)

**Applications:**
Antigen in ELISA and Western blots, excellent antigen for detection of HHV-4 (EBV) with minimal specificity problems.

**Description:**
The protein contains the EBV early antigen protein fragment, amino acids: 306-390. The protein is purified by proprietary chromatographic technique.

**Background:**
Epstein-Barr virus, frequently referred to as EBV, is a member of the gamma herpesvirus family and one of the most common human viruses. The virus occurs worldwide, and most people become infected with EBV sometime during their lives. It persists in B lymphocytes for the life of the host. IgG to the early antigen appears in the acute phase and generally falls to undetectable levels after 3 to 6 months. In many people, detection of antibody to the early antigen is a sign of active infection, but 20% of healthy people may have this antibody for years.

**Specificity:**
Immunoreactive with all sera of EBV infected individuals.

**Selected References:**
- Jones et al. (2003) Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing. Virology. 313:663.